Joint Transnational Call (JTC2015)

These projects were funded under E-Rare.

Factsheet (PDF)

General information
Topic: Transnational Research Projects on Rare Diseases
Budget: 19,2 Million €
Funded projects: 19
The following parties have decided to open the seventh E-Rare joint transnational call (JTC 2015) for funding multilateral research projects on rare diseases together with the European Commission (EC) under the ERA-NET Cofund mechanism: 

  • The Austrian Science Fund (FWF), Austria
  • The Astrian Research Promotion Agency (FFG), Austria
  • The Research Foundation – Flanders (FWO), Belgium, Flanders
  • Fund for Scientific Research – FNRS (F.R.S – FNRS), Belgium, French speaking community
  • The Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
  • Le Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
  • The Genome Canada (GC), Canada
  • The French National research Agency (ANR), France
  • The Federal Ministry of Education and Research (BMBF), Germany
  • The German Research Foundation (DFG), Germany
  • The General Secretariat for Research and Technology (GSRT), Greece
  • The Hungarian Scientific Research Fund (OTKA), Hungary
  • The Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
  • The Italian Ministry of Health (MoH), Italy
  • The Regione Emilia-Romagna – Agenzia Sanitaria e Sociale Regionale (RER-ASSR), Italy
  • The Latvian Academy of Sciences (LAS), Latvia
  • The National Centre for Research and Development (NCBR), Poland
  • The Foundation for Science and Technology (FCT), Portugal
  • The Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
  • The National Institute of Health Carlos III (ISCIII), Spain
  • The Swiss National Science Foundation (SNSF), Switzerland
  • The Netherlands Organization for Health Research and Development (ZonMw), The Netherlands
  • The Scientific and Technological Research Council of Turkey (TÜBITAK), Turkey
  • INSTINCT: Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease
  • SMART-HaemoCare: Small Antibody Fragment as Alternative Tools in Haemophilia Care
  • NSEuroNet : European network on Noonan syndrome and related disorders
  • PERescue : Translating Peroxisome Biogenesis Disorders: Identifying Pharmacological Therapies and Clinical Trial Endpoints
  • Propekal5: Tracing the untackled facets of Peeling Skin Disease-Targeting epidermal proteolysis for treatment
  • EuroCID: Non-SCID combined immunodeficiencies: a diagnostic and therapeutic challenge
  • iNSC-WMD: Patient-Derived Glial Precursor Cell Therapy for Vanishing White Matter Disease
  • ImproveCPVT: Improving diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia: integrating clinical and basic science
  • GENOMIT: Mitochondrial Disorders: from a genome-wide Registry to medical genomics, toward molecular mechanisms and new therapies
  • INSAID: A comprehensive clinical and experimental approach to personalized molecular medicine in patients with defined and undefined autoinflammatory disorders
  • EURO-CDG-2: A European research network directed towards improving diagnosis and treatment of inborn glycosylation disorders.
  • ERAdicatPH: Understanding primary hyperoxaluria type 1 towards the development of innovative therapeutic strategies.
  • KLKIN: Netherton Syndrome; From mechanism to therapies
  • CoHEART: Improving Care for Cohesinopathies from heart phenotypes to novel therapies
  • CMT-NRG: Modulation of Neuregulin signaling as an effective strategy to treat hereditary neuropathies (Charcot-Marie-Tooth disease)
  • GETHERTHALPLUS: Novel Gene Therapy for Thalassemia: Pre-clinical Development and Assessment in Animal and Stem Cell Models
  • PREPARE: Preparing for therapies in autosomal recessive ataxias
  • Hipbi-RD: Harmonising phenomics information for a better interoperability in the RD field
  • EuroDBA: The European Diamond-Blackfan Anemia Consortium